The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.
Denise Aysel Yardley
Consultant or Advisory Role - Genentech (U)
Ian E. Krop
Consultant or Advisory Role - Genentech/Roche (U)
Research Funding - Genentech
Patricia LoRusso
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Nicholas J. Robert
Honoraria - Roche
Research Funding - Genentech/Roche
Musa Mayer
No relevant relationships to disclose
Oyewale O. Abidoye
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Catherine Lai
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bongin Yoo
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Edith A. Perez
No relevant relationships to disclose